372 / 1498
Conclusions
• Large numbers of well conduction RCT supporting CMT in early stage
HL
• Lack of randomised trials comparing chemotherapy alone vs
contemporary CMT.
• Recent FDG-PET data inform patient specific discussions about risk of
relapse (increased with chemo alone) versus late toxicity (increased with
CMT)
• Response adapted treatment using FDG PET
-
Ongoing challenges to
implement in routine clinical practice and QA measures are required to
meet Deauville criteria